Abstract
We studied whether the reduction in bone turnover by use of antiresorptive drugs is detrimental in patients with diabetes who already have low bone turnover due to hyperglycemia in a nationwide cohort study from Denmark. All users of antiresorptive drugs against osteoporosis between 1996 and 2006 (n = 103,562) were the exposed group, with three age- and gender-matched controls from the general population (n = 310,683). Patients on bisphosphonates and raloxifene had a higher risk of hip, spine, and forearm fractures. However, no difference was observed in the antifracture efficacy between patients with diabetes and nondiabetic controls or between patients with type 1 and type 2 diabetes. Too few were users of strontium to allow analysis for this compound. The excess risk of fractures among patients treated with bisphosphonates or raloxifene compared to nonexposed controls was due to the higher a priori risk of fractures among patients treated for osteoporosis. Diabetes does not seem to affect the fracture-preventive potential of bisphosphonates or raloxifene. The low-turnover state of diabetes thus does not seem to be a hindrance to the effect of these drugs against osteoporosis. Therefore, patients with diabetes should receive treatment for osteoporosis in the same way as nondiabetic patients.
Similar content being viewed by others
References
Vestergaard P (2007) Discrepancies in bone mineral density and fracture risk in patients with type 1 and type 2 diabetes—a meta-analysis. Osteoporos Int 18:427–444
Janghorbani M, van Dam R, Willett W, Hu F (2007) Systematic review of type 1 and type 2 diabetes mellitus and risk of fracture. Am J Epidemiol 166:495–505
Follak N, Kl”ting I, Wolf E, Merk H (2004) Improving metabolic control reverses the histomorphometric and biomechanical abnormalities of an experimentally induced bone deficit in spontaneously diabetic rats. Calcif Tissue Int 74:551–560
Achemlal L, Tellal S, Rkiouak F, Nouijai A, Bezza A, Derouiche EM, Ghafir D, El Maghraoui A (2005) Bone metabolism in male patients with type 2 diabetes. Clin Rheumatol 24:493–496
Bouillon R (1992) Diabetic bone disease. Low turnover osteoporosis related to decreased IGF-I production. Verh K Acad Geneeskd Belg 54:365–392
Berberoglu Z, Gursoy A, bayraktar N, Yazici A, Tutuncu N, Demirag N (2007) Rosiglitazone decreases serum bone specific alkaline phosphatase activity in postmenopausal diabetic women. J Clin Endocrinol Metab 92:3523–3530
Kindblom JM, Ohlsson C, Ljunggren O, Karlsson MK, Tivesten A, Smith U, Mellström D (2009) Plasma osteocalcin is inversely related to fat mass and plasma glucose in elderly Swedish men. J Bone Miner Res 24:867–874
Akin O, Gol K, Akturk M, Erkaya S (2003) Evaluation of bone turnover in postmenopausal patients with type 2 diabetes mellitus using biochemical markers and bone mineral density measurements. Gynecol Endocrinol 17:19–29
Gerdhem P, Isaksson A, Akesson K, Obrant K (2005) Increased bone density and decreased bone turnover, but no evident alteration of fracture susceptibility in elderly women with diabetes mellitus. Osteoporos Int 16:1506–1512
Lee N, Sowa H, Hinoi E, Ferron M, Ahn J, Confavreux C, Dacquin R, Mee P, McKee M, Jung D, Zhang Z, Kim J, Mauvais-Jarvis F, Ducy P, Karsenty G (2007) Endocrine regulation of energy metabolism by the skeleton. Cell 130:456–469
Clowes J, Allen H, Prentis D, Eastell R, Blumsohn A (2003) Octreotide abolishes the acute decrease in bone turnover in response to oral glucose. J Clin Endocrinol Metab 88:4867–4873
Black D, Greenspan S, Ensrud K, Palermo L, McGowan J, Lang T, Garnero P, Bouxsein M, Bilezikian J, Rosen C (2003) The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N Engl J Med 349:1207–1215
Bonnick S, Saag K, Kiel D, McClung M, Hochberg M, Burnett S, Sebba A, Kagan R, Chen E, Thompson D, de Papp A (2006) Comparison of weekly treatment of postmenopausal osteoporosis with alendronate versus risedronate over two years. J Clin Endocrinol Metab 91:2631–2637
Lufkin E, Whitaker M, Nickelsen T, Argueta R, Caplan R, Knickerbocker R, Riggs B (1998) Treatment of established postmenopausal osteoporosis with raloxifene: a randomized trial. J Bone Miner Res 13:1747–1754
Mashiba T, Turner CH, Hirano T, Forwood MR, Jacob DS, Johnston CC, Burr DB (2001) Effects of high-dose etidronate treatment on microdamage accumulation and biomechanical properties in beagle bone before occurrence of spontaneous fractures. Bone 29:271–278
Lenart BA, Lorich DG, Lane JM (2008) Atypical fractures of the femoral diaphysis in postmenopausal women taking alendronate. N Engl J Med 358:1304–1306
Lenart BA, Neviaser AS, Lyman S, Chang CC, Edobor-Osula F, Steele B, van der Meulen MCH, Lorich DG, Lane JM (2009) Association of low-energy femoral fractures with prolonged bisphosphonate use: a case control study. Osteoporos Int 20:1353–1362
Dagdelen S, Sener D, Bayraktar M (2007) Influence of type 2 diabetes mellitus on bone mineral density response to bisphosphonates in late postmenopausal osteoporosis. Adv Ther 24:1314–1320
Keegan THM, Schwartz AV, Bauer DC, Sellmeyer DE, Kelsey JL (2004) Effect of alendronate on bone mineral density and biochemical markers of bone turnover in type 2 diabetic women: the fracture intervention trial. Diabetes Care 27:1547–1553
Andersen T, Madsen M, Jørgensen J, Mellemkjær L, Olsen J (1999) The Danish National Hospital Register. Dan Med Bull 46:263–268
Mosbech J, Jørgensen J, Madsen M, Rostgaard K, Thornberg K, Poulsen T (1995) The Danish National Patient Register: evaluation of data quality [in Danish]. Ugeskr Laeger 157:3741–3745
Lévesque LE, Hanley JA, Kezouh A, Suissa S (2010) Problem of immortal time bias in cohort studies: example using statins for preventing progression of diabetes. BMJ 340:b5087
Black D, Cummings S, Karpf D, Cauley J, Thompson D, Nevitt M, Bauer D, Genant H, Haskell W, Marcus R, Ott S, Torner J, Quandt S, Reiss T, Ensrud K (1996) Randomised trial of the effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535–1541
Abbassy MA, Watari I, Soma K (2010) The effect of diabetes mellitus on rat mandibular bone formation and microarchitecture. Eur J Oral Sci 118:364–369
Hamada Y, Kitazawa S, Kitazawa R, Fujii H, Kasuga M, Fukagawa M (2007) Histomorphometric analysis of diabetic osteopenia in streptozotocin-induced diabetic mice: a possible role of oxidative stress. Bone 40:1408–1414
Ferron M, Hinoi E, Karsenty G, Ducy P (2008) Osteocalcin differentially regulates beta cell and adipocyte gene expression and affects the development of metabolic diseases in wild-type mice. Proc Natl Acad Sci USA 105:5266–5270
Fujii H, Hamada Y, Fukagawa M (2008) Bone formation in spontaneously diabetic Torii—newly established model of non-obese type 2 diabetes rats. Bone 42:372–379
McNair P, Madsbad S, Christensen M, Christiansen C, Faber O, Binder C, Transbøl I (1979) Bone mineral loss in insulin-treated diabetes mellitus: studies on pathogenesis. Acta Endocrinol 90:463–472
Acknowledgments
This study was funded by an unrestricted grant from Servier Denmark and the Dandy Foundation. None of the sponsors had any role in obtaining data, analyzing data, or writing the report.
Author information
Authors and Affiliations
Corresponding author
Additional information
The authors have stated that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Vestergaard, P., Rejnmark, L. & Mosekilde, L. Are Antiresorptive Drugs Effective Against Fractures in Patients with Diabetes?. Calcif Tissue Int 88, 209–214 (2011). https://doi.org/10.1007/s00223-010-9450-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00223-010-9450-4